The Rosen Law Firm, P.A., a global investor rights law firm, announces
it is investigating potential securities claims on behalf of
shareholders of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) resulting
from allegations that AcelRx may have issued materially misleading
business information to the investing public.
On March 9, 2015, the Company announced that last week it had received
correspondence from the Food and Drug Administration (“FDA”) stating
that in addition to the bench testing and two Human Factors studies that
have already been performed, an additional clinical study is needed to
assess the risk of inadvertent dispensing and overall risk of dispensing
failures. On this news, shares of AcelRx fell over 1/3 during intraday
trading on March 9, 2015.
The Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by AcelRx investors. If you purchased shares of AcelRx before
March 9, 2015, please visit the website at http://rosenlegal.com/cases-538.html
for more information. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email
at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Copyright Business Wire 2015